Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.

Abstract

Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety.

AIM:

The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA.

MATERIALS & METHODS:

Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with RA. Results: ABCG2 rs2231142 A allele conferred a higher response to IGU, while NAT2 rs1495742 G carriersconferred a lower response to IGU. CYP2C19*2 rs4244285 A carriers had higher risk for IGU-induced toxicity compared to the GG carriers.

CONCLUSION:

Our study suggests that the polymorphisms of ABCG2 (rs2231142), NAT2 (rs1495741)and CYP2C19*2 (rs4244285) may help to predict thetherapeutic effectiveness and toxicity of IGU in patients with RA.

• Authors: Wenjing Xiao, Jian-Ping Guo, Chun Li, Hua Ye, Wei Wei, Yaohong Zou, Lie Dai, Zhijun Li, Miaojia Zhang, Xiangpei Li, Xiaoyan Cai, Jianhong Zhao, Youlian Wang, Yi Tao, Dongzhou Liu, Yasong Li, Min Wu, Erwei Sun, Lijun Wu, Li Luo, Rong Mu, Zhanguo Li
• Journal: Pharmacogenomics (Pharmacogenomics) Vol. 19 Issue 5 Pg. 383-392 (04 2018) ISSN: 1744-8042 [Electronic] England
• PMID: 29517409 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antirheumatic Agents
• Chromones
• Sulfonamides
• iguratimod
• DNA

Topics

• Adult
• Aged
• Antirheumatic Agents (adverse effects, metabolism, therapeutic use)
• Arthritis, Rheumatoid (drug therapy, genetics)
• China
• Chromones (adverse effects, metabolism, therapeutic use)
• DNA (genetics)
• Female
• Genetic Carrier Screening
• Genotype
• Heterozygote
• Humans
• Male
• Middle Aged
• Polymorphism, Single Nucleotide (genetics)
• Predictive Value of Tests
• Risk Assessment
• Sulfonamides (adverse effects, metabolism, therapeutic use)